Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Juni 2026 09:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.
22. Mai 2026 09:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
04. Mai 2026 09:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics announced new data in metastatic colorectal cancer, demonstrating 3-4x improvement in duration response vs. historical 4-6 month benchmark.
27. April 2026 08:10 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Oncolytics Biotech announced Type C meeting with the FDA aligning on the design of clinical study to support approval of pelareorep in patients with SCAC.